Bioventus Selects Bazis NN as Distributor of DUROLANE® in Russia
15.6.2020 16:00:00 EEST | Business Wire | Press release
Bioventus, a global leader in orthobiologic solutions, has selected Bazis NN as its authorized distributor for DUROLANE, its single-injection joint-fluid osteoarthritis (OA) treatment. OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200615005023/en/
DUROLANE is a single-injection, hyaluronic acid product used for joint lubrication in the treatment of pain associated with osteoarthritis in the knee, hip and small joints. (Photo: Business Wire)
According to official statistics, patients with OA make up one quarter of all patients with musculoskeletal system diseases and OA is detected in 4% of the entire adult population.1 Hyaluronic acid (HA)-based products like DUROLANE and DUROLANE SJ help manage pain in the knees, hips, wrists, elbows, ankles, finger and toe joints of patients with OA.
“We believe the OA market in Russia is underserved and the patients there will benefit greatly from DUROLANE,” said John Nosenzo, Chief Commercial Officer, Bioventus. “Bazis has a terrific track record in marketing and selling orthopaedic solutions in Russia and we are pleased they are helping Bioventus reach more patients and physicians with our proven pain reliever for osteoarthritis.”
“Bazis has been serving patients and physicians in Russia for more than 16 years,” said Aleksandr Alekseev, Director, Bazis NN. “We are excited to offer DUROLANE for knee and hip and DUROLANE SJ for small joints. Both are safe, single injection options for patients that provide powerful and long-lasting OA pain relief.”
DUROLANE and DUROLANE SJ are produced using a natural, safe and proven process called NASHA ® . This process yields stabilized (HA) which is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. It has been proven to provide greater reduction in OA knee pain versus Synvisc-One®2* and longer lasting pain relief versus a steroid injection3. DUROLANE is also safe for repeated courses of therapy. Repeated use of DUROLANE does not increase the incidence of adverse events.4
About Bioventus
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, www.bioventusglobal.com and follow the company on LinkedIn and Twitter.
Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark. Synvisc-One and Synvisc are registered trademarks of Genzyme Corporation.
Summary of Indication for Use: DUROLANE (3ml): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. DUROLANE SJ (1ml): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes. DUROLANE SJ is also indicated for pain following joint arthroscopy in the presence of osteoarthritis within three months of the procedure. There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant and breastfeeding women, and in children. Risks can include transient pain, swelling and/or stiffness at the injection site. Indications presented are those approved in Russia; indications and product offerings vary by country. Consult with your local Bioventus representative for approved use within your region of interest. Full prescribing information can be found in product labeling, at www.durolane.com.(1mL / 3mL).
References: 1. Kabalyk M.A. Prevalence of Osteoarthritis in Russia: Regional Aspects of Trends in Statistical Parameters During 2011–2016 Rheumatology Science and Practice. 2018;56(4):416-422. (In Russ.) doi:10.14412/1995-4484-2018-416-422. 2. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis. 2013; 2(1):108. doi:10.4172/2167-7921.1000108. 3. Leighton R, Åkermark C, Therrien R, et. al. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014; 22(1):17-25. 4. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2018.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005023/en/
Contact information
Thomas Hill
919-474-6715
thomas.hill@bioventusglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexGen’s HybridOS Energy Management System Receives ISO 9001:2015 Certification, Strengthening Its Platform to Serve International Markets29.7.2026 15:00:00 EEST | Press release
FlexGen Power Systems, LLC. (“FlexGen”), a leading battery energy storage system and energy management software provider, today announced that its HybridOS energy management platform is ISO 9001:2015 certified. ISO 9001:2015 is an internationally recognized standard for quality management, meaning the systems and processes behind HybridOS, from design, development, deployment, and remote software support, have been accredited by the certification body. “Battery storage is critical infrastructure for keeping the lights on, but it can only do its job if grid operators can trust it to perform when it’s needed,” said Mike Wallace, Managing Director of Europe for FlexGen. “Security, safety, and quality must be built into every layer of battery storage technology to ensure it can be relied on to power industry, mission-critical systems, and residences. High availability, high performance, and high security standards are all a must for battery storage assets needed across the globe.” This cer
Copeland Enters into Exclusive Negotiations to Acquire Dickson, Advancing Cold Chain Leadership29.7.2026 15:00:00 EEST | Press release
Copeland, a global leader in compression technologies and controls solutions, today announced its entry into exclusive negotiations towards the purchase of Dickson, a portfolio company of May River Capital and provider of environmental monitoring and cloud-native software solutions for regulated life sciences and healthcare applications. The proposed acquisition will strengthen Copeland’s strategy of enabling an efficient and effective cold chain, building on its existing stationary and in-transit monitoring capabilities to deliver an end-to-end solution that helps healthcare, pharmaceutical and life sciences customers safeguard product integrity, maintain compliance and reduce operational risk. Quality assurance and environmental monitoring represents a large and secularly growing market opportunity, driven by increasing regulatory requirements, the expansion of biologics and cell and gene therapies, and rising demand for supply chain transparency. Dickson's cloud-native monitoring pl
Wind Point Partners Announces Final Close of Oversubscribed Fund XI at $3.2 Billion29.7.2026 15:00:00 EEST | Press release
Wind Point Partners (“Wind Point”), a leading Chicago-based private equity firm, today announced the successful closing of its latest fund, Wind Point Partners XI (“Fund XI” or the “Fund”). Fund XI was oversubscribed and exceeded the hard cap, with total commitments of $3.2 billion. This amount includes significant commitments by the General Partner and members of the firm’s Executive Advisor Partner (“EAP”) program, providing strong alignment across all investors in the Fund. Fund XI represents Wind Point’s largest fund to date and its most global and diverse investor base in the firm’s 42-year history. Fund XI received commitments from more than 65 global institutions spanning 17 countries, including pension funds, insurance companies, asset managers, family offices and foundations. Propelled by significant repeat support from existing investors, the efficient fundraise process was completed in under nine months. Founded in 1984, Wind Point has a long history of partnering with top-c
Workiva Launches Specialized AI Agents and Intelligence Layer to Advance High-Stakes Reporting29.7.2026 15:00:00 EEST | Press release
Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, today announced three purpose-built AI agents and Workiva Knowledge, a persistent intelligence layer grounded in an organization's data, instructions, and content. The agents will help customers in advanced solution tiers accelerate reporting and compliance outcomes with the control and traceability of the Workiva platform. Together, these capabilities offer enterprise teams governed AI at the speed and scale their organizations require. "Finance, sustainability, risk, and compliance teams are moving from execution to orchestration as AI agents take on more of the work, and we're building the platform that makes that transformation possible," said Deepak Bharadwaj, Chief Product Officer of Workiva. "As we evolve the Workiva platform, we're staying true to what our customers have always counted on us to deliver: accuracy, transparency, and solutions shaped by the reality and complexity
Xpress Genomics Joins Parse Biosciences’ Certified Service Provider Network29.7.2026 15:00:00 EEST | Press release
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing, and a QIAGEN company, today announced that Xpress Genomics has joined its Certified Service Provider (CSP) program, becoming the first in the Nordic region. The Stockholm-based company will offer Parse's Evercode single cell sequencing portfolio to researchers through its existing sequencing service pipeline. Originating out of the Karolinska Institutet in 2022, Xpress Genomics has built automated, in-house workflows for NGS projects. Joining the CSP program adds Evercode to the company's service offerings, giving its customers direct access to Parse's split-pool single cell technology. "Our customers expect fast, high-quality results," said Christoph Ziegenhain, CEO at Xpress Genomics. "Offering Evercode through our CSP membership gives them a strong option for single cell projects, backed by the same turnaround and quality standards our lab runs on." "Adding Xpress Genomics to our CSP program m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom